Thomas J Marrie1, Gregory J Tyrrell2, Sumit R Majumdar3, Dean T Eurich4. 1. Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada. Electronic address: t.marrie@dal.ca. 2. Division of Diagnostic and Applied Microbiology, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada. 3. Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta and The Provincial Laboratory for Public Health, Edmonton, Canada. 4. School of Public Health, University of Alberta, Edmonton, Canada.
Abstract
BACKGROUND: Although a considerable amount is known about the effect of age on the manifestations and outcomes of pneumonia, the same is not true for invasive pneumococcal disease. METHODS: This was a prospective observational study of all cases (2435) of invasive pneumococcal disease in adults in Northern Alberta from 2000 to 2014. Rates of invasive pneumococcal disease per 100,000, sociodemographic variables, clinical characteristics, and invasive pneumococcal disease-related outcomes were compared for the following age groups: 17-54, 55-64, 65-74, and ≥75 years. RESULTS: The rate of invasive pneumococcal disease per 100,000 increased with increasing age. Although only 27.3% of the cases were in those aged ≥65 years, they accounted for 48% of the deaths. The case fatality rate increased with increasing age, from 9.6% for those aged 17-54 years to 31.7% for those aged ≥75 years. The rate of meningitis decreased with increasing age, as did admission to intensive care and use of mechanical ventilation. There was a marked reduction in the rate of invasive pneumococcal disease due to protein conjugate vaccine 7 and protein conjugate vaccine 13 serotypes in those aged ≥55 years but a much smaller decline in rates for those aged 17-54 years. Replacement with non-vaccine serotypes constituted approximately 50% of the cases. CONCLUSIONS: The rate of invasive pneumococcal disease is highest in the very elderly, and manifestations of invasive pneumococcal disease are influenced by age.
BACKGROUND: Although a considerable amount is known about the effect of age on the manifestations and outcomes of pneumonia, the same is not true for invasive pneumococcal disease. METHODS: This was a prospective observational study of all cases (2435) of invasive pneumococcal disease in adults in Northern Alberta from 2000 to 2014. Rates of invasive pneumococcal disease per 100,000, sociodemographic variables, clinical characteristics, and invasive pneumococcal disease-related outcomes were compared for the following age groups: 17-54, 55-64, 65-74, and ≥75 years. RESULTS: The rate of invasive pneumococcal disease per 100,000 increased with increasing age. Although only 27.3% of the cases were in those aged ≥65 years, they accounted for 48% of the deaths. The case fatality rate increased with increasing age, from 9.6% for those aged 17-54 years to 31.7% for those aged ≥75 years. The rate of meningitis decreased with increasing age, as did admission to intensive care and use of mechanical ventilation. There was a marked reduction in the rate of invasive pneumococcal disease due to protein conjugate vaccine 7 and protein conjugate vaccine 13 serotypes in those aged ≥55 years but a much smaller decline in rates for those aged 17-54 years. Replacement with non-vaccine serotypes constituted approximately 50% of the cases. CONCLUSIONS: The rate of invasive pneumococcal disease is highest in the very elderly, and manifestations of invasive pneumococcal disease are influenced by age.
Authors: Nikolai Siemens; Sonja Oehmcke-Hecht; Thomas C Mettenleiter; Bernd Kreikemeyer; Peter Valentin-Weigand; Sven Hammerschmidt Journal: Front Microbiol Date: 2017-12-21 Impact factor: 5.640
Authors: Danielle A Wagner-Muñiz; Shannon L Haughney; Sean M Kelly; Michael J Wannemuehler; Balaji Narasimhan Journal: Front Immunol Date: 2018-03-02 Impact factor: 7.561
Authors: Maria Drayß; Heike Claus; Kerstin Hubert; Katrin Thiel; Anja Berger; Andreas Sing; Mark van der Linden; Ulrich Vogel; Thiên-Trí Lâm Journal: PLoS One Date: 2019-02-08 Impact factor: 3.240
Authors: Emily Mosites; Tammy Zulz; Dana Bruden; Leisha Nolen; Anna Frick; Louisa Castrodale; Joseph McLaughlin; Chris Van Beneden; Thomas W Hennessy; Michael G Bruce Journal: Emerg Infect Dis Date: 2019-10 Impact factor: 6.883
Authors: Aleksandr G Chuchalin; Gennadiy G Onishchenko; Victor P Kolosov; Olga P Kurganova; Tatiana A Zaitseva; Leonid G Manakov; Galina N Kholodok; Juliy M Perelman; Roman S Kozlov; Natalia M Ivakhnishina; Olga E Trotsenko; Albina P Bondarenko Journal: Interdiscip Perspect Infect Dis Date: 2019-02-18
Authors: Ashley Makwana; Shamez N Ladhani; Georgia Kapatai; Ella Campion; Norman K Fry; Carmen Sheppard Journal: Emerg Infect Dis Date: 2018-10 Impact factor: 6.883